FMW0 Stock Chart & Stats
€3.44
€0.00(0.00%)
At close: 4:00 PM EDT
€3.44
€0.00(0.00%)
Day’s Range― - ―
52-Week Range€3.09 - €4.22
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
€31.17M
Enterprise Value€23.01
Total Cash (Recent Filing)€30.76M
Total Debt (Recent Filing)€2.83M
Price to Earnings (P/E)―
Beta0.32
Next Earnings
Aug 10, 2026EPS Estimate
-0.28Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.80
Shares Outstanding16,050,320
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio0.06
Price to Book (P/B)3.04
Price to Sales (P/S)0.00
P/FCF Ratio-1.85
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€21.72Price Target Upside531.35% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-0.89
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical Efficacy On Physical FunctionRobust Phase IIb functional results materially lower development risk for an enobosarm claim tied to preservation of lean mass and physical function. Durable clinical differentiation versus GLP-1s can support label claims, payer coverage, and partner interest, improving long-term commercial prospects.
Strategic Supply Partnership With Novo NordiskA clinical-supply agreement with a market-leading GLP-1 maker de-risks trial execution, lowers trial cash requirements, and signals strategic validation. Novo Nordisk's involvement and RFN creates durable partnering optionality, improving odds of co-development or licensing outcomes.
Improved Near-term Liquidity And Reduced BurnA larger cash balance and reduced operating burn extend runway to a key interim readout, lowering near-term financing pressure. Sustained cost discipline and available funds increase the probability management can reach pivotal milestones without immediate dilution, supporting development continuity.
Bears Say
Persistent Negative Cash FlowChronic negative operating and free cash flow indicate the business is not self-funding and will need external capital or large partner payments to continue. This structural cash burn constrains strategic flexibility, raises dilution risk, and makes long-term planning contingent on successful clinical milestones or financings.
Minimal Revenue And Ongoing LossesNear-zero recurring product revenue and sustained net losses mean the company lacks commercial cash generation to support growth. Without meaningful revenue diversification or steady product sales, funding and commercialization depend on one-off transactions, milestones, or additional capital raises.
Regulatory And Competitive Complexity With GLP-1sA need for agent-specific pivotal studies and competing market dominance by large GLP-1 players raises development complexity, cost, and time to market. This structural hurdle reduces labeling and commercial clarity, increases required investment, and may limit uptake absent strong comparative or complementary data.
Veru News
FMW0 FAQ
What was Veru’s price range in the past 12 months?
Veru lowest stock price was €3.09 and its highest was €4.22 in the past 12 months.
What is Veru’s market cap?
Veru’s market cap is €31.17M.
When is Veru’s upcoming earnings report date?
Veru’s upcoming earnings report date is Aug 10, 2026 which is in 6 days.
How were Veru’s earnings last quarter?
Veru released its earnings results on May 13, 2026. The company reported -€0.113 earnings per share for the quarter, beating the consensus estimate of -€0.248 by €0.135.
Is Veru overvalued?
According to Wall Street analysts Veru’s price is currently Undervalued.
Does Veru pay dividends?
Veru does not currently pay dividends.
What is Veru’s EPS estimate?
Veru’s EPS estimate is -0.28.
How many shares outstanding does Veru have?
Veru has 16,050,320 shares outstanding.
What happened to Veru’s price movement after its last earnings report?
Veru reported an EPS of -€0.113 in its last earnings report, beating expectations of -€0.248. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Veru?
Currently, no hedge funds are holding shares in DE:FMW0
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Veru Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
-62.50%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
31.86%
Trailing 12-Months
Company Description
Veru
Veru Inc. operates as a biopharmaceutical firm primarily dedicated to advancing novel therapeutic agents for various types of cancer. Commercially, Veru markets the FC2 internal condom, designed to offer dual protection against both unplanned pregnancies and the transmission of sexually transmitted infections. This product is distributed globally to a diverse clientele, including governmental health departments, UN organizations, non-profit entities, and commercial distributors. Its robust development pipeline features a range of investigational therapies, notably within oncology: Enobosarm, an orally administered selective androgen receptor agonist, is progressing through Phase III clinical trials for treating metastatic breast cancer that is AR+, ER+, and HER2-negative. Sabizabulin is undergoing Phase IIb studies for the same type of metastatic breast cancer. Furthermore, a combination therapy of Enobosarm with abemaciclib is in Phase III for AR+ ER+ HER2- metastatic breast cancer. For metastatic triple-negative breast cancer, Veru is exploring a combination of Sabizabulin (an oral targeted cytoskeleton disruptor) and Enobosarm (a selective androgen receptor agonist) in Phase II trials. The company's portfolio also extends to prostate cancer: Sabizabulin is in Phase II trials for metastatic castration and androgen receptor targeting agent-resistant prostate cancer. VERU-100, a GnRH antagonist peptide delivered via injection, is also in Phase II for advanced hormone-sensitive prostate cancer. Beyond oncology, Veru is investigating other conditions: Zuclomiphene Citrate is in Phase II for managing hot flashes. Sabizabulin has reached Phase III for treating SARS-CoV-2 in high-risk patients susceptible to acute respiratory distress syndrome. Additionally, the firm is developing a novel pharmaceutical formulation aimed at alleviating lower urinary tract symptoms associated with an enlarged prostate in men. Originally established as The Female Health Company in 1971, the corporation adopted the name Veru Inc. in July 2017. Its corporate headquarters are situated in Miami, Florida.
FMW0 Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call reported meaningful clinical progress (positive Phase IIb functional results, active enrollment in a pivotal-feeding Phase IIb plateau study with interim readout expected Q1 2027) and materially improved near-term liquidity and expense trends. At the same time, Veru remains unprofitable, faces label and regulatory complexity (possible need for agent-specific studies or function/BMD endpoints), stiff competition from established GLP-1 players, and dependence on nonrecurring gains and an interim milestone for runway. On balance, the progress on clinical endpoints, the clear regulatory strategy contingencies, and improved cash position outweigh the operational and regulatory risks discussed.View all DE:FMW0 earnings summariesFMW0 Stock 12 Month Forecast
Average Price Target
€21.72
▲(531.35% Upside)
Technical Analysis
Karyopharm Therapeutics
―
Cue Biopharma
―
Inmune Bio
―
Celularity
―
Jupiter Neurosciences, Inc.
―